All In Biotech

Drug Trial Radar · NCT07583446

Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock

A Randomized, Double-blind, Phase 2b/3 Clinical Study of Istaroxime Combined With Standard Care Versus Placebo and Standard of Care for the Treatment of Cardiogenic Shock (CS) Society for Cardiovascular Angiography and Interventions (SCAI) Stage B or C Due to Acute Heart Failure (AHF)

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Sep 9, 2026

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
May 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if the drug istaroxime works to treat cardiogenic shock due to acute heart failure in adults. It will also learn about the safety of istaroxime. Researchers will compare istaroxime to a placebo (a look-alike substance that contains no drug) to see if istaroxime works to treat cardiogenic shock due to acute heart failure. The main questions it aims to answer are: * Does istaroxime relieve participants' shortness of breath compared to a placebo? * Does istaroxime provide clinical benefit in terms of lowering the risk of dying, having invasive procedures, being rehospitalized or having worsening heart failure, and/or increasing quality of life compared to a placebo? * Does istaroxime reduce the duration of the initial hospital stay compared with placebo? Participants will: * Receive a 48-hour intravenous infusion of istaroxime or placebo with possible additional retreatment depending on their clinical condition * Complete questionnaires rating their breathing and describing their quality of life * Return for visits 30 and 90 days after the start of Cycle 1 infusion. The trial will end when the last participant completes Day 30 and all participants have been followed for at least 30 days after their last IMP exposure. At trial termination, participants who have not been followed to Day 90 will have an end-of-study (EOS) visit.

Conditions

  • Cardiogenic Shock

Interventions

  • istaroximeDrug

    intravenous istaroxime

  • placeboDrug

    intravenous placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in participant-reported dyspneaTime frame: 24 hours
  2. Hierarchical composite endpointTime frame: 30 days; EQ-VAS change from baseline to 48 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Surgery Mikayelyan CJSC

    Yerevan, Armenia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.